Wednesday, December 06, 2023 BLC4 primary publication: Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer. Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM, Lerner SP. SWOG S1605. European Urology 84: 536-544. 2023. https://www.sciencedirect.com/science/article/pii/S0302283823030191 The researchers tested intravenous immunotherapy (atezolizumab) in patients with high-risk non–muscle-invasive bladder cancer that recurred after BCG (bacillus Calmette-Guérin) treatment. Although found similar outcomes to previous trials, the benefit of this therapy is modest and needs to be carefully balanced with the significant risk of side effects. For more information please visit the BLC4 members trial page.
